Audit: QRS - Kratom for Health & Longevity

Audit conducted on 22/09/2026 04:36 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	86
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span against the ER: protocol cells vs ER Therapeutic Protocol, time cells vs Practical Considerations and Therapeutic Protocol half-life bullet, gates vs Key Interactions & Contraindications, markers vs the ER biomarker table.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Lede keeps the ER’s hedges (“consistently described but barely measured”, “uncommon but occasionally severe”).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications stay absolute (pregnancy “at any dose”); no ER caution upgraded or downgraded.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefit/risk tiers, contraindications and interactions each map to their own ER section; no modifying factor surfaced as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, author names, NCT identifiers or brand names anywhere in the QRS; drug examples in Key Interactions are the ER’s own.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s sober, trade-off framing.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert and data-driven while remaining neutral.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents evidence and thresholds, no prescriptive voice.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Disclaimer is template text; body makes no clinical recommendation.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Declarative statements throughout; no “recommend”/”advise” verbs.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person forms anywhere in the rendered content.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are the ER’s own biomarker names; lede is plain.
2.8	Information is presented in a concise and very compact manner	🟢	Every field is a compressed fragment (longest populated span 604 characters, the 7-item contraindication list).
2.9	It DOES NOT address the reader directly	🟢	No second-person address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Thresholds, dose ranges and biomarker targets assume a proactive, self-monitoring reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Protocol, monitoring cadence and qualitative tracking all assume effortful follow-through.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content density and clinical detail are not general-population material.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Lede states the costs are better established than the gains, matching the ER’s weighting for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	Neither “anti-aging” nor “longevity” appears outside the title, which carries the ER’s canonical topic.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Formal terminology throughout (“myocardial infarction”, “alanine aminotransferase”, “whole dried leaf powder”); no consumer-grade route language.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and the Marker/Target/Why headers are byte-identical to the template.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template span names present; marker_#* expanded to 8 rows and qualitative_item# to 7 items, 65 spans total.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff of lines 15-412 against the template shows only the <title> changed; the website=”evidence_review” / “audit” / “full_review” spans are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the only tier without items is the High benefit tier, handled under 12.5 by hiding the span.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Dose form and amount”, “Single versus split dosing” and “Best time of day” are the ER’s bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker names copied from the ER biomarker column; no abbreviation or invention.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters anywhere in the file.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Each section is condensed to fragments while retaining the completeness that 8.2, 9.2, 14.2 and 15.2 require; nothing is carried beyond a single sheet’s budget.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment occupies lines 2-14, immediately after <!doctype html> and before any other comment or head content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Inside an HTML comment; not echoed anywhere on the sheet.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, which the colon requires.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: kratom_2026-0922-0007_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.9.11, matching this QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0922-0418.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Nickname plus version number, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: kratom_2026-0922-0007_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Kratom for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Kratom for Health & Longevity”, the ER canonical_topic, entity-encoded.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	qrs_creation_date 2026-0922-0418 renders as 09/22/2026.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Subline carries only the template’s date / source / AI4L / model elements.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion: mechanism duality, described-but-unmeasured benefits, the better-established costs, and the polysubstance death pattern.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause traces to a distinct Conclusion passage (dose decides which; consistently described; costs better established; nearly every death involved other depressants).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “opioids”, “stimulants”, “depressant substances” are the ER’s own plain terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes or statistics.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items come from the ER’s “Populations who should avoid Kratom” list.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER avoid-populations are represented, one to one.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Rationale clauses stripped (“given documented neonatal withdrawal requiring treatment”, “where kratom can precipitate withdrawal”, “in whom no safety data exist”); no citations or study detail.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Child-Pugh Class B or C, three times the upper reference limit, QTc above 470/480 ms and the 90-day infarction window are all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER uses no ranking notation in this list; items are plain comma-separated.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, and the ER names seven populations that should avoid kratom.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The Contraindications section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All items come from the ER Key Interactions & Contraindications bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Ten ER interaction bullets carried plus Z-drugs split out of the benzodiazepine bullet; opioid analgesics and benzodiazepines are correctly omitted because the contraindication list already covers full agonists and benzodiazepines.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eleven <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Only the class plus its example drugs survives; mechanism and mitigation clauses are stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists retained for CYP3A4 substrates, CYP2D6 substrates, CYP3A4 inhibitors, P-glycoprotein substrates, antihistamines, sedating botanicals and supplements.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	No ranking notation in the ER bullets; lists are plain comma-separated.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, and the ER names twelve interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The Key Interactions section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three action cells derive from ER Therapeutic Protocol bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose form and amount, single versus split dosing, and best time of day are the three decision-bearing implementation aspects of the ER protocol.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section contains eleven actionable bullets, well more than three.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Each label, value and sub carries ER-sourced content, including the 25-31 mg per serving and 50-135 mg daily figures.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Pain tolerance at one hour, stimulation at 15-30 minutes, and blood-level accumulation over 8-9 days are the ER’s three time-to-effect statements.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered pain tolerance (first Medium benefit) then low-dose stimulation (third Medium benefit) then the pharmacokinetic accumulation window.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER states three distinct time-to-effect aspects, so no set is unused.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time fields populated from the ER Practical Considerations time-to-effect bullet, the pain-tolerance magnitude and the half-life bullet.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the row is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Tiers mirror the ER Expected Benefits subsections.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and correctly named.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-separated list of ER benefit headings with no effect sizes or qualifiers.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content carried; the ER’s “⚠️ Conflicted” marker is dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER records no High-tier benefit, and benefits_high is emptied with style=”display: none” rather than given empty-state text.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Tiers mirror the ER Potential Risks & Side Effects subsections.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and correctly named.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only; all ten Low-tier risks compressed to bare noun phrases.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No frequencies, severity grades or study detail carried.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER Monitoring Protocol & Defining Success biomarker table.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER biomarker rows present, with targets and rationale preserved.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline, 6-week, 4-week, 6-month and 6-12-month cadence plus the jaundice/dark urine/itching trigger, matching the ER narrative.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER’s qualitative-markers list in the same section.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER qualitative markers present as qualitative_item_1 through 7.

Issues 22/09/2026 04:36

Pass rate 100.00%. No issues found.

Issues 22/09/2026 04:26

1. 4.5 — Sheet overflows one A4 page: At the template’s type scale the populated sheet renders well past one A4 page, and the compressible surfaces were left at ER length — [action_1_sub]/[action_2_sub]/[action_3_sub] (lines 456-488) wrap to 4-5 lines each in 60mm cells, [time_2_sub] and [time_3_sub] (lines 518, 532) to 4 lines, [risks_low] (lines 641-648) runs 422 characters, eleven Monitoring target/why cells wrap to a second table line, and [monitoring_cadence] (line 795) wraps to 4 lines.
2. 9.2 — Alcohol interaction omitted: The ER’s Alcohol bullet (line 361) is missing from [caution_items] (lines 592-617); the Contraindications list covers only “an active alcohol use disorder” (line 584), not alcohol co-use generally, which the ER names as part of its single largest risk modifier (line 334).

Fixes 22/09/2026 04:26

1. 9.2 — Alcohol interaction added: Inserted <li>Alcohol</li> into [caution_items], covering the ER’s Alcohol bullet that the Contraindications list did not already absorb.
2. 4.5 — Protocol sub-cells condensed: Tightened [action_1_sub], [action_2_sub] and [action_3_sub] from 4-5 wrapped lines to 3 each, dropping redundant framing while keeping every dose figure and timing fact.
3. 4.5 — Time-to-effect sub-cells condensed: Trimmed [time_2_sub] to the onset and peak figures alone and reduced [time_3_sub]’s half-life clause to “mean terminal half-life 43–68 hours”, saving a wrapped line in each.
4. 4.5 — Monitoring cells condensed: Shortened eleven [marker_#_target]/[marker_#_why] cells to single table lines (e.g. “Under 25 U/L in men, under 20 U/L in women” to “Under 25 U/L men, 20 U/L women”; “Rapid heart rate and raised blood pressure are the commonest cardiovascular effects” to “The commonest cardiovascular effects”), and removed the label repetition from [marker_2_target].
5. 4.5 — Low-risk tier condensed: Reduced [risks_low] from 422 to 329 characters by shortening item names while keeping all ten ER Low-tier risks distinguishable.
6. 4.5 — Cadence and interaction lists condensed: Trimmed [monitoring_cadence] from 4 wrapped lines to 3 with all cadence points intact, and shortened the [caution_items] parenthetical drug lists (“Over-the-counter sedating antihistamines” to “Sedating antihistamines”, “high-dose magnesium, iron, calcium carbonate” to “magnesium, iron, calcium”).